�ݺ�ߣshows by User: SachaHenry3

�ݺ�ߣshows by User: SachaHenry3 / http://www.slideshare.net/images/logo.gif �ݺ�ߣshows by User: SachaHenry3 / Wed, 20 Dec 2017 11:23:56 GMT �ݺ�ߣShare feed for �ݺ�ߣshows by User: SachaHenry3 Applied Digital Pathology in Colon and Lung Cancer Research /slideshow/vikotr-koelzer/84534311 v-171220112356
Vikotr Koelzer at the Digital Pathology Conference 2017]]>
Vikotr Koelzer at the Digital Pathology Conference 2017]]> Wed, 20 Dec 2017 11:23:56 GMT /slideshow/vikotr-koelzer/84534311 SachaHenry3@slideshare.net(SachaHenry3) Applied Digital Pathology in Colon and Lung Cancer Research SachaHenry3 Vikotr Koelzer at the Digital Pathology Conference 2017 <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/v-171220112356-thumbnail.jpg?width=120&height=120&fit=bounds" /> Vikotr Koelzer at the Digital Pathology Conference 2017

Applied Digital Pathology in Colon and Lung Cancer Research from William Baird

]]> 226 9 https://cdn.slidesharecdn.com/ss_thumbnails/v-171220112356-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post

http://activitystrea.ms/schema/1.0/posted

0 RNA Biomarker Discovery in Exosomes and Liquid Biopsies by Sequencing and qPCR /slideshow/rna-biomarker-discovery-in-exosomes-and-liquid-biopsies-by-sequencing-and-qpcr/80598364 precisionslides4-171009081805
Made at the 4th Global Precision Medicine and Biomarkers Leaders Summit: Europe by Peter Mouritzen. For more information visit http://www.global-engage.com/wp-content/uploads/2017/04/Global-Precision-Medicine-Biomarkers-Europe-2017.pdf. To identify new biomarkers and develop minimal invasive tests, we have developed robust methods for next generation sequencing of smallRNA in biofluids. For high-throughput profiling microRNA in biofluids, highly sensitive LNA™-based qPCR is applied. Recent results will be discussed from the prostate cancer program.]]>
Made at the 4th Global Precision Medicine and Biomarkers Leaders Summit: Europe by Peter Mouritzen. For more information visit http://www.global-engage.com/wp-content/uploads/2017/04/Global-Precision-Medicine-Biomarkers-Europe-2017.pdf. To identify new biomarkers and develop minimal invasive tests, we have developed robust methods for next generation sequencing of smallRNA in biofluids. For high-throughput profiling microRNA in biofluids, highly sensitive LNA™-based qPCR is applied. Recent results will be discussed from the prostate cancer program.]]> Mon, 09 Oct 2017 08:18:05 GMT /slideshow/rna-biomarker-discovery-in-exosomes-and-liquid-biopsies-by-sequencing-and-qpcr/80598364 SachaHenry3@slideshare.net(SachaHenry3) RNA Biomarker Discovery in Exosomes and Liquid Biopsies by Sequencing and qPCR SachaHenry3 Made at the 4th Global Precision Medicine and Biomarkers Leaders Summit: Europe by Peter Mouritzen. For more information visit http://www.global-engage.com/wp-content/uploads/2017/04/Global-Precision-Medicine-Biomarkers-Europe-2017.pdf. To identify new biomarkers and develop minimal invasive tests, we have developed robust methods for next generation sequencing of smallRNA in biofluids. For high-throughput profiling microRNA in biofluids, highly sensitive LNA™-based qPCR is applied. Recent results will be discussed from the prostate cancer program. <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/precisionslides4-171009081805-thumbnail.jpg?width=120&height=120&fit=bounds" /> Made at the 4th Global Precision Medicine and Biomarkers Leaders Summit: Europe by Peter Mouritzen. For more information visit http://www.global-engage.com/wp-content/uploads/2017/04/Global-Precision-Medicine-Biomarkers-Europe-2017.pdf. To identify new biomarkers and develop minimal invasive tests, we have developed robust methods for next generation sequencing of smallRNA in biofluids. For high-throughput profiling microRNA in biofluids, highly sensitive LNA™-based qPCR is applied. Recent results will be discussed from the prostate cancer program.

RNA Biomarker Discovery in Exosomes and Liquid Biopsies by Sequencing and qPCR from William Baird

]]> 421 4 https://cdn.slidesharecdn.com/ss_thumbnails/precisionslides4-171009081805-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post

http://activitystrea.ms/schema/1.0/posted

0 Precision Medicine- Growth Opportunities for Genomics Technologies /slideshow/precision-medicine-growth-opportunities-for-genomics-technologies/80598348 precisionslides3-171009081729
Made at the 4th Global Precision Medicine and Biomarkers Leaders Summit: Europe by Nitin Naik. For more information visit http://www.global-engage.com/wp-content/uploads/2017/04/Global-Precision-Medicine-Biomarkers-Europe-2017.pdf. Better understanding of disease heterogeneity and identification of novel targets will expand precision medicine applications beyond oncology and foster collaboration between pharmaceutical companies, diagnostic manufacturers, payers and providers to develop new products and services. In next three years, Clinical sequencing technologies and NGS informatics & services represent the largest growth potential. Other emerging technologies such as liquid biopsy and point-of-care testing technologies will start to compete against established NGS space for precision diagnostics. This briefing will provide strategic insights into growth opportunities related to Genomics, Molecular Diagnostics, and Sequencing Technologies shaping the future of Global Precision Medicine industry. It will specifically highlight global & regional initiatives, game changing companies and disruptive technologies (big data, cloud, predictive analytics) shaping new business models.]]>
Made at the 4th Global Precision Medicine and Biomarkers Leaders Summit: Europe by Nitin Naik. For more information visit http://www.global-engage.com/wp-content/uploads/2017/04/Global-Precision-Medicine-Biomarkers-Europe-2017.pdf. Better understanding of disease heterogeneity and identification of novel targets will expand precision medicine applications beyond oncology and foster collaboration between pharmaceutical companies, diagnostic manufacturers, payers and providers to develop new products and services. In next three years, Clinical sequencing technologies and NGS informatics & services represent the largest growth potential. Other emerging technologies such as liquid biopsy and point-of-care testing technologies will start to compete against established NGS space for precision diagnostics. This briefing will provide strategic insights into growth opportunities related to Genomics, Molecular Diagnostics, and Sequencing Technologies shaping the future of Global Precision Medicine industry. It will specifically highlight global & regional initiatives, game changing companies and disruptive technologies (big data, cloud, predictive analytics) shaping new business models.]]> Mon, 09 Oct 2017 08:17:29 GMT /slideshow/precision-medicine-growth-opportunities-for-genomics-technologies/80598348 SachaHenry3@slideshare.net(SachaHenry3) Precision Medicine- Growth Opportunities for Genomics Technologies SachaHenry3 Made at the 4th Global Precision Medicine and Biomarkers Leaders Summit: Europe by Nitin Naik. For more information visit http://www.global-engage.com/wp-content/uploads/2017/04/Global-Precision-Medicine-Biomarkers-Europe-2017.pdf. Better understanding of disease heterogeneity and identification of novel targets will expand precision medicine applications beyond oncology and foster collaboration between pharmaceutical companies, diagnostic manufacturers, payers and providers to develop new products and services. In next three years, Clinical sequencing technologies and NGS informatics & services represent the largest growth potential. Other emerging technologies such as liquid biopsy and point-of-care testing technologies will start to compete against established NGS space for precision diagnostics. This briefing will provide strategic insights into growth opportunities related to Genomics, Molecular Diagnostics, and Sequencing Technologies shaping the future of Global Precision Medicine industry. It will specifically highlight global & regional initiatives, game changing companies and disruptive technologies (big data, cloud, predictive analytics) shaping new business models. <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/precisionslides3-171009081729-thumbnail.jpg?width=120&height=120&fit=bounds" /> Made at the 4th Global Precision Medicine and Biomarkers Leaders Summit: Europe by Nitin Naik. For more information visit http://www.global-engage.com/wp-content/uploads/2017/04/Global-Precision-Medicine-Biomarkers-Europe-2017.pdf. Better understanding of disease heterogeneity and identification of novel targets will expand precision medicine applications beyond oncology and foster collaboration between pharmaceutical companies, diagnostic manufacturers, payers and providers to develop new products and services. In next three years, Clinical sequencing technologies and NGS informatics & services represent the largest growth potential. Other emerging technologies such as liquid biopsy and point-of-care testing technologies will start to compete against established NGS space for precision diagnostics. This briefing will provide strategic insights into growth opportunities related to Genomics, Molecular Diagnostics, and Sequencing Technologies shaping the future of Global Precision Medicine industry. It will specifically highlight global & regional initiatives, game changing companies and disruptive technologies (big data, cloud, predictive analytics) shaping new business models.

Precision Medicine- Growth Opportunities for Genomics Technologies from William Baird

]]> 618 6 https://cdn.slidesharecdn.com/ss_thumbnails/precisionslides3-171009081729-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post

http://activitystrea.ms/schema/1.0/posted

0 Expanding Precision Medicine & Biomarker Strategy Options with RNAscope /slideshow/expanding-precision-medicine-biomarker-strategy-options-with-rnascope/80598337 precisionslides2-171009081701
Made at the 4th Global Precision Medicine and Biomarkers Leaders Summit: Europe by Christopher Bunker. For more information visit http://www.global-engage.com/wp-content/uploads/2017/04/Global-Precision-Medicine-Biomarkers-Europe-2017.pdf. Detection of biomarkers within the morphological context of tissue samples allows to assess interactions between cell type as well as heterogeneity. ACD has developed a novel RNA ISH technology called RNAscope® to detect any RNA species in FFPE and fresh or fixed frozen tissue or cell samples. It can be multiplexed, performed manually or by automation, and in many cases combined with IHC. The unique probe design and signal amplification system allows the visualisation of each individual target RNA molecules as a single dot. The RNAscope assay has been applied in a broad range of research areas, including immuno-oncology, neuroscience, stem cells, inflammation and infectious disease and has been widely adopted in biotech and pharmaceutical R&D in various fields like drug safety, target and biomarker validation, the latter already in the process of the development of companion diagnostics.]]>
Made at the 4th Global Precision Medicine and Biomarkers Leaders Summit: Europe by Christopher Bunker. For more information visit http://www.global-engage.com/wp-content/uploads/2017/04/Global-Precision-Medicine-Biomarkers-Europe-2017.pdf. Detection of biomarkers within the morphological context of tissue samples allows to assess interactions between cell type as well as heterogeneity. ACD has developed a novel RNA ISH technology called RNAscope® to detect any RNA species in FFPE and fresh or fixed frozen tissue or cell samples. It can be multiplexed, performed manually or by automation, and in many cases combined with IHC. The unique probe design and signal amplification system allows the visualisation of each individual target RNA molecules as a single dot. The RNAscope assay has been applied in a broad range of research areas, including immuno-oncology, neuroscience, stem cells, inflammation and infectious disease and has been widely adopted in biotech and pharmaceutical R&D in various fields like drug safety, target and biomarker validation, the latter already in the process of the development of companion diagnostics.]]> Mon, 09 Oct 2017 08:17:01 GMT /slideshow/expanding-precision-medicine-biomarker-strategy-options-with-rnascope/80598337 SachaHenry3@slideshare.net(SachaHenry3) Expanding Precision Medicine & Biomarker Strategy Options with RNAscope SachaHenry3 Made at the 4th Global Precision Medicine and Biomarkers Leaders Summit: Europe by Christopher Bunker. For more information visit http://www.global-engage.com/wp-content/uploads/2017/04/Global-Precision-Medicine-Biomarkers-Europe-2017.pdf. Detection of biomarkers within the morphological context of tissue samples allows to assess interactions between cell type as well as heterogeneity. ACD has developed a novel RNA ISH technology called RNAscope® to detect any RNA species in FFPE and fresh or fixed frozen tissue or cell samples. It can be multiplexed, performed manually or by automation, and in many cases combined with IHC. The unique probe design and signal amplification system allows the visualisation of each individual target RNA molecules as a single dot. The RNAscope assay has been applied in a broad range of research areas, including immuno-oncology, neuroscience, stem cells, inflammation and infectious disease and has been widely adopted in biotech and pharmaceutical R&D in various fields like drug safety, target and biomarker validation, the latter already in the process of the development of companion diagnostics. <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/precisionslides2-171009081701-thumbnail.jpg?width=120&height=120&fit=bounds" /> Made at the 4th Global Precision Medicine and Biomarkers Leaders Summit: Europe by Christopher Bunker. For more information visit http://www.global-engage.com/wp-content/uploads/2017/04/Global-Precision-Medicine-Biomarkers-Europe-2017.pdf. Detection of biomarkers within the morphological context of tissue samples allows to assess interactions between cell type as well as heterogeneity. ACD has developed a novel RNA ISH technology called RNAscope® to detect any RNA species in FFPE and fresh or fixed frozen tissue or cell samples. It can be multiplexed, performed manually or by automation, and in many cases combined with IHC. The unique probe design and signal amplification system allows the visualisation of each individual target RNA molecules as a single dot. The RNAscope assay has been applied in a broad range of research areas, including immuno-oncology, neuroscience, stem cells, inflammation and infectious disease and has been widely adopted in biotech and pharmaceutical R&D in various fields like drug safety, target and biomarker validation, the latter already in the process of the development of companion diagnostics.

Expanding Precision Medicine & Biomarker Strategy Options with RNAscope from William Baird

]]> 972 5 https://cdn.slidesharecdn.com/ss_thumbnails/precisionslides2-171009081701-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post

http://activitystrea.ms/schema/1.0/posted

0 Success through novel collaborations, value-added services, and early patient involvement /slideshow/success-through-novel-collaborations-valueadded-services-and-early-patient-involvement/80598327 precisionslides-171009081627
Presentation was made at the 4th Global Precision Medicine and Biomarkers Leaders Summit: Europe by Armin Furtwangler. For more information visit http://www.global-engage.com/wp-content/uploads/2017/04/Global-Precision-Medicine-Biomarkers-Europe-2017.pdf. Success through novel collaborations, valueadded services, and early patient involvement. Development of just new medications will no longer be a viable business model for the pharmaceutical industry in the short- to midterm. Therefore, we are working on innovative offerings for patients, doctors, and payers. These include, among many others, point-of care diagnostics, enabling quicker, diagnoses in a targeted manner. Other approaches include “smart devices”, applying modern sensor technologies, as well as “gamification” and other behavioural modification approaches to enhance patient compliance and adherence to their individual medications. The key to future success lies in collaborations with new partners, valueadded services, as well as application of innovative technologies, and most importantly – early involvement of patients at every step in the development process.]]>
Presentation was made at the 4th Global Precision Medicine and Biomarkers Leaders Summit: Europe by Armin Furtwangler. For more information visit http://www.global-engage.com/wp-content/uploads/2017/04/Global-Precision-Medicine-Biomarkers-Europe-2017.pdf. Success through novel collaborations, valueadded services, and early patient involvement. Development of just new medications will no longer be a viable business model for the pharmaceutical industry in the short- to midterm. Therefore, we are working on innovative offerings for patients, doctors, and payers. These include, among many others, point-of care diagnostics, enabling quicker, diagnoses in a targeted manner. Other approaches include “smart devices”, applying modern sensor technologies, as well as “gamification” and other behavioural modification approaches to enhance patient compliance and adherence to their individual medications. The key to future success lies in collaborations with new partners, valueadded services, as well as application of innovative technologies, and most importantly – early involvement of patients at every step in the development process.]]> Mon, 09 Oct 2017 08:16:27 GMT /slideshow/success-through-novel-collaborations-valueadded-services-and-early-patient-involvement/80598327 SachaHenry3@slideshare.net(SachaHenry3) Success through novel collaborations, value-added services, and early patient involvement SachaHenry3 Presentation was made at the 4th Global Precision Medicine and Biomarkers Leaders Summit: Europe by Armin Furtwangler. For more information visit http://www.global-engage.com/wp-content/uploads/2017/04/Global-Precision-Medicine-Biomarkers-Europe-2017.pdf. Success through novel collaborations, valueadded services, and early patient involvement. Development of just new medications will no longer be a viable business model for the pharmaceutical industry in the short- to midterm. Therefore, we are working on innovative offerings for patients, doctors, and payers. These include, among many others, point-of care diagnostics, enabling quicker, diagnoses in a targeted manner. Other approaches include “smart devices”, applying modern sensor technologies, as well as “gamification” and other behavioural modification approaches to enhance patient compliance and adherence to their individual medications. The key to future success lies in collaborations with new partners, valueadded services, as well as application of innovative technologies, and most importantly – early involvement of patients at every step in the development process. <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/precisionslides-171009081627-thumbnail.jpg?width=120&height=120&fit=bounds" /> Presentation was made at the 4th Global Precision Medicine and Biomarkers Leaders Summit: Europe by Armin Furtwangler. For more information visit http://www.global-engage.com/wp-content/uploads/2017/04/Global-Precision-Medicine-Biomarkers-Europe-2017.pdf. Success through novel collaborations, valueadded services, and early patient involvement. Development of just new medications will no longer be a viable business model for the pharmaceutical industry in the short- to midterm. Therefore, we are working on innovative offerings for patients, doctors, and payers. These include, among many others, point-of care diagnostics, enabling quicker, diagnoses in a targeted manner. Other approaches include “smart devices”, applying modern sensor technologies, as well as “gamification” and other behavioural modification approaches to enhance patient compliance and adherence to their individual medications. The key to future success lies in collaborations with new partners, valueadded services, as well as application of innovative technologies, and most importantly – early involvement of patients at every step in the development process.

Success through novel collaborations, value-added services, and early patient involvement from William Baird

]]> 273 7 https://cdn.slidesharecdn.com/ss_thumbnails/precisionslides-171009081627-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post

http://activitystrea.ms/schema/1.0/posted

0 https://public.slidesharecdn.com/v2/images/profile-picture.png https://cdn.slidesharecdn.com/ss_thumbnails/v-171220112356-thumbnail.jpg?width=320&height=320&fit=bounds slideshow/vikotr-koelzer/84534311 Applied Digital Pathol... https://cdn.slidesharecdn.com/ss_thumbnails/precisionslides4-171009081805-thumbnail.jpg?width=320&height=320&fit=bounds slideshow/rna-biomarker-discovery-in-exosomes-and-liquid-biopsies-by-sequencing-and-qpcr/80598364 RNA Biomarker Discover... https://cdn.slidesharecdn.com/ss_thumbnails/precisionslides3-171009081729-thumbnail.jpg?width=320&height=320&fit=bounds slideshow/precision-medicine-growth-opportunities-for-genomics-technologies/80598348 Precision Medicine- Gr...